The unique properties of a cancer cell are acquired through a stepwise accumulation of heritable changes in the information content of proto-oncogenes and tumor suppressor genes. While gain, loss, and mutation of genetic information have long been known to contribute to tumorigenesis, it has been increasingly recognized over the past 5 years that 'epigenetic' mechanisms may play an equally important role. The main epigenetic modification of the human genome is methylation of cytosine residues within the context of the CpG dinucleotide. De novo methylation of 'CpG islands' in the promoter regions of tumor suppressor genes may lead to transcriptional silencing through a complex process involving histone deacetylation and chromatin condensation, and thus represents a tumorigenic event that is functionally equivalent to genetic changes like mutation and deletion. DNA methylation is interesting from a diagnostic viewpoint because it may be easily detected in DNA released from neoplastic and preneoplastic lesions into serum, urine or sputum, and from a therapeutic viewpoint because epigenetically silenced genes may be reactivated by inhibitors of DNA methylation and/or histone deacetylase. A better understanding of epigenetic mechanisms leading to tumor formation and chemoresistance may eventually improve current cancer treatment regimens and be instructive for a more rational use of anticancer agents.
focusing on (i) the distribution and maintenance of DNA methylation in normal cells (ii) DNA methylation-mediated silencing of tumor suppressor genes in cancer (iii) the use of DNA methylation events as tumor biomarkers, and (iv) the use of DNA methylation events as targets for anticancer therapy. We also briefly discuss current methods to detect changes in DNA methylation in clinical specimens.
DNA methylation, CpG islands, and DNA methyltransferases
To appreciate how changes in DNA methylation may impinge on the properties of a cell during tumorigenesis, it is necessary to first consider the distribution and function of DNA methylation in normal cells. DNA methylation in the human genome occurs nearly exclusively at cytosine residues within the symmetric dinucleotide, CpG (Fig. 1A) . Methylated cytosine accounts for 0.75-1% of the total DNA bases, and 70% of all CpG dinucleotides are methylated (2) . Methylated cytosines are widely spread throughout the genome, with particularly high densities in the promoters of retroviruses and transposons that have accumulated in the genome (2) . Unmethylated CpG sites are primarily confined to DNA regions with high relative densities of CpG, socalled 'CpG islands'. The human genome contains roughly 29, 000 CpG islands (3, 4) that are distributed in a non-random pattern, with a preference for the promoter and first exon regions of protein coding genes. While most CpG islands remain free of methylation and are associated with transcriptionally active genes, predominantly so-called 'housekeeping' genes, certain CpG islands are normally methylated, including those associated with imprinted genes and genes on the inactive X chromosome (5).
The DNA methylation pattern of a cell is accurately reproduced after DNA synthesis and is stably transmitted to the daughter cells. The covalent addition of methyl groups to CpG sites in the newly synthesized DNA strand is mediated by an enzyme known as DNA methyltransferase 1 (DNMT1) (Fig. 1B) (2). This enzyme is targeted to the replication fork where it efficiently methylates DNA containing hemi-methylated CpGs (postreplicative maintenance methylation). Two additional active DNA methyltransferases have been cloned, DNMT3A and DNMT3B, both of which catalyze the transfer of methyl groups to 'naked' DNA (de novo methylation) (2) .
Translating the information content of DNA methylation
The methylation state of promoter CpG islands confers information about the transcriptional activity at these loci. It has been known for many years that, in general terms, there is an inverse relationship between the density of promoter methylation and the transcriptional activity of a gene (Fig. 2) . However, the actual mechanisms by which DNA methylation modulates gene expression have remained elusive. Early experiments showed that methylation of specific DNA sequences can prevent the binding of some ubiquitous transcription factors. While this model is certainly an attractive one, it can explain only a minority of cases where methylation causes stable transcriptional silencing of genes. An alternative model implicates changes in the architecture of the nucleosomal core as the repressive element (Fig. 3) . This model was reinforced by the recent identification of a family of proteins that preferentially bind to methyl-CpG (methyl-CpG-binding proteins) (6) . Some of these proteins have been directly implicated in methylation-dependent gene silencing by recruiting histone deacetylases to the sites of methylation.
Histone deacetylates catalyze the removal of acetyl groups from the core histones, converting the open, transcriptionally competent chromatin structure into a closed structure that can no longer be accessed by the basal transcriptional machinery (Fig. 3) . The linkage between methyl-CpG-binding proteins, histone deacetylases and the chromatin remodeling machinery has provided a basis for understanding how DNA methylation may mediate a transcriptionally incompetent chromatin state.
Recently, it was shown that DNA methyltransferases can also recruit histone deacetylases to methylated sites (reviewed in (7)).
The relative roles of DNA methyltransferases and methyl-CpGbinding proteins in conferring stable transcriptional repression remain to be determined.
Changes in promoter methylation during tumor progression
Compared with their normal counterparts, cancer cells exhibit significant changes in DNA methylation patterns, which can generally be summarized as global hypomethylation of the genome accompanied by focal hypermethylation events (8) . The origin of these changes is largely unknown; searches for genetic 
Methods to detect DNA methylation events in clinical specimens
Detection of methylated cytosine at specific sites in DNA from clinical specimens is notoriously difficult because the methylation signature is erased during conventional procedures used to amplify DNA, including cloning and polymerase chain reaction (PCR). Southern blot analysis of DNA digested with methylationsensitive restriction endonucleases has previously been an indispensable tool in the study of DNA methylation, but has now been replaced by PCR methods that are based on initial modification of DNA with bisulfite (Fig. 4) . Bisulfite selectively deaminates cytosine residues to uracil, leaving methylated cytosines intact (10) , and the modified DNA can be used as a template in a standard PCR using primers specific for the gene of interest (11) . Sequence analysis of the resulting PCR product provides an accurate display of methylated cytosines (11), but may be technically difficult and labor intensive. A variety of PCR methods have been developed, including methylation-specific PCR (12), methylation-sensitive single nucleotide primer extension (Ms-SNuPE) (13) , and methods based on the use of restriction endonucleases (14, 15) , which are simple to use but all suffer from the drawback that only a limited number of CpG sites can be analyzed in each assay.
Recently, three PCR methods have been described that resolve differentially methylated DNA sequences on the basis of differences in melting temperature. The overall methylation status of a CpG island may be determined directly after PCR by melting analysis in the reaction tube, provided that the thermal cycler is coupled to a fluorometer (LightCycler or equivalent) (16) . For more refined resolution of differentially methylated alleles, the Fig. 4 . PCR methods for detection of methylated cytosine. Prior to PCR, DNA is modified with bisulfite to convert unmethylated cytosine to uracil. The modified DNA can be used as a template for methylation-specific PCR (12), Ms-SNuPE (13), or a PCR with primers that do discriminate between methylated and unmethylated alleles. Products generated by non-discriminatory PCR can be further analyzed by sequence analysis (11), melting analysis (melting curve analysis (16), DGGE (17), or DHPLC (18)), or digestion with restriction endonucleases (14) .
PCR product may be subjected to melting analysis in a polyacrylamide gel containing a gradient of chemical denaturants (DGGE) (17) or by denaturing high performance liquid chromatography (DHPLC) (18) .
The most widely used of the above methods is methylationspecific PCR, which uses primers that are specific for bisulfitemodified DNA and discriminate between methylated and unmethylated alleles of a given gene. A potential pitfall inherent in the use of this method is the very high sensitivity (<0.1%),
implying that a positive signal may be obtained from 'background' methylation of unknown biological significance (17, 19) . Data obtained by methylation-specific PCR should, if not generated in a real-time quantitative format (20) , be confirmed by one or more alternative methods to obtain information about the fraction of methylated alleles.
Changes in DNA methylation as a tumor biomarker
There is an urgent need of novel approaches for early diagnosis of cancer and detection of recurrence. In this respect, an important discovery was that DNA is released from tumor cells and may be Tumor-specific DNA may be easily obtained in a non-invasive way from the site where the cancer occurs, for example in the sputum of lung cancer patients or the urine from patients with prostate cancer. It has even been documented that significant amounts of circulating tumor DNA may be isolated from the serum of cancer patients (22) . A particularly exciting study showed that one of two methylation markers was always positive in tumor and sputum DNA from patients with lung cancer, and that tumor-specific methylation changes could be detected in sputum samples up to 3 years prior to clinical diagnosis (23) . However, a major drawback of drugs targeting the DNA methylation or histone acetylation machineries is that they lack specificity. Concomitant activation of genes that are normally silenced, but contribute to cellular immortalization and tumor progression in the activated state, may significantly compromise the beneficial effects of these drugs. Future research will be directed at developing more refined strategies to reactivate specific genes.
Reversal of drug resistance
Although chemotherapeutic drugs are widely used in the cure and palliation of human malignancies, intrinsic and acquired drug resistance remains the most unpredictable factor affecting che- 
